PBA
ALKS icon

Paradigm Biocapital Advisors’s Alkermes ALKS Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ALKS Stock Details ALKS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,719,334
Closed -$51.6M – 33
2025
Q3 		$51.6M Buy
1,719,334
+343,765
+25% +$9.69M 1.47% 20
2025
Q2 		$39.4M Buy
+1,375,569
New +$40.9M 1.68% 18

Other funds holding ALKS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paradigm Biocapital Advisors's ALKS Position: Q4 2025 in Review

Paradigm Biocapital Advisors sold out of Alkermes (ALKS) in Q4 2025, closing a stake of 1,719,334 shares — an estimated $51.6M sold.

Paradigm Biocapital Advisors first reported a position in ALKS in Q2 2025 and held it in 2 quarters. The position peaked at $51.6M in Q3 2025. 366 funds tracked by Wall St. Rank hold ALKS as of Q4 2025.

  • Paradigm Biocapital Advisors reported no remaining Alkermes position as of Q4 2025 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 1,719,334 Alkermes shares in Q4 2025, an estimated $51.6M.
  • Paradigm Biocapital Advisors first reported a position in Alkermes in Q2 2025 and held it in 2 quarters.
  • Paradigm Biocapital Advisors's Alkermes position peaked at $51.6M in Q3 2025.
  • 366 funds tracked by Wall St. Rank held Alkermes as of Q4 2025.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.